CYP2C9
HGNC:2623 · 31 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CYP2C9 | “The primary meta-analysis revealed a high-certainty association between VKORC1 and CYP2C9 variants and warfarin sensitivity, with variant carriers requiring a substantially lower maintenance dose (pooled mean difference: -20.68 mg/week; 95% confidence interval [CI]: -35.66 to -5.70).” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “This review examines current evidence on how selected herbal extracts influence key enzymes such as cytochrome P450 family 3 subfamily A member 4 (CYP3A4), cytochrome P450 family 2 subfamily D member 6 (CYP2D6), cytochrome P450 family 2 subfamily C member 9 (CYP2C9), and UDP-glucuronosyltransferases (UGTs), and highlights the implications for drug safety and efficacy.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “The drug metabolism analysis revealed that 25% of approved drugs undergo Phase 1 metabolism via CYP3A4, followed by the combined involvement of CYP3A4 and CYP2C9 for 10% of approved drugs.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “The subjects with genotype CYP2C9 *1/*3 depicted a 4-fold higher (AUC0-∞) as compared to that of the CYP2C9 *1/*1 population.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “The Genetic Polymorphisms of CYP2C9 and VKORC1 in the Saudi Population and Their Impact on Anticoagulant Management.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “We assessed the performance of seven sequence-based (SIFT, PolyPhen2, mutation accessor, FATHMM, PhD-SNP, MutPred2, and SNPs & Go) and five structure-based (mCSM, SDM, DDGun, CupSat, and MAESTROweb) tools in predicting the impact of 118 nsSNPs in the CYP2C19, CYP2C9, CYP2B6, CYP2D6, and DPYD genes with known function (24 normal, one increased, 42 decreased, and 51 no-function).” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “In in silico ADME prediction, ALC was shown to have poor water solubility and high gastrointestinal absorption along with inhibition of some cytochrome P450s (CYP2C19 and CYP2C9) without inhibition of others (CYP1A2, CYP3A4, and CYP2D6) and P-glycoprotein substrate.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Association of CYP2C9*2 Allele with Sulphonylurea-Induced Hypoglycaemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun Population.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Association of CYP2C9∗3 and CYP2C8∗3 Non-Functional Alleles with Ibuprofen-Induced Upper Gastrointestinal Toxicity in a Saudi Patient.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “The genetic association tests showed that VKORC1 (rs9923231, and rs61742245), CYP2C9 (rs98332238, rs9332172, rs1057910, rs9332230, rs1799853, rs1057911, and rs9332119), CYP2C19 (rs28399511, and rs3758581), and CYP2C8 (rs11572080 and rs10509681) were significantly associated with warfarin weekly dose.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “The cytochrome P450 genes (CYP2C9, CYP2C19, and CYP2D6) were estimated to impact responses of 54.3% (n = 1,156,113) of the used drugs (27.2% are possibly affected by CYP2C9, 12.8% by CYP2C19, and 14.3% by CYP2D6).” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Individual studies demonstrated the association of CYP2C9, SLCO1B1, and MTNR1B variants with the safety and efficacy of nateglinide.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “We mined next generation sequencing (NGS) data from 11,889 unrelated Saudi nationals, to determine the presence and frequencies of known functional SNP variants in 8 clinically relevant pharmacogenes (CYP2C9, CYP2C19, CYP3A5, CYP4F2, VKORC1, DPYD, TPMT and NUDT15), recommended by the Clinical Pharmacogenetics Implementation Consortium (CPIC), and collectively identified 82 such star alleles.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Using this approach, we replicate 11 known drug-gene interactions including, for example, CYP2C9/CYP2C8 variants and sulfonylurea/thiazolidinedione prescribing and ABCB1/ABCG2 variants and statin prescribing.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “BACKGROUND: Several studies optimized the warfarin dose based on CYP2C9*2, CYP2C9*3, VKORC1 -1639 G > A, CYP4F2 V433M.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “It is commonly used to reduce the risk of blood coagulation in patients diagnosed with acute coronary syndrome, or ischemic stroke.Area covered: We reviewed published articles in PubMed and Google Scholar that focused on the mutations of CYP2C19, CYP3A4, CYP2C9, CYP2B6, and CYP1A2 genes related to clopidogrel clinical efficacy and safety.Expert opinion: Based on current pharmacogenetic studies, patients carrying CYP2C19*2, CYP2C19*3, CYP2C9*3, and CYP2B6*5 alleles may not respond to clopidogrel due to poor platelet inhibition efficacy revealed among them.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “We aimed to summarize and investigate the current evidence regarding the frequency of CYP2D6, CYP2C9, CYP2C19, and MDR1 in Saudi Arabia.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations With Type 2 Diabetes: A Case-Control Study.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Therefore, this study aims to determine if there is any single nucleotide polymorphism (SNP) within CYP19A1, CYP2C19, CYP2C9, CYP1B1, CYP3A4, and CYP1A2 genes associated with BC in the Jordanian population.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “In this review, we discuss some of the most clinically important CYPs isoforms (CYP2D6, CYP2A6, CYP2C19, CYP2C9, CYP1B1 and CYP1A2) with respect to gene polymorphisms and drug metabolism.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Association of CYP2C9 Genetic Variants with Vitiligo.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Genotyping of cytochrome P450 enzymes CYP2B6, CYP2C9, CYP2C19, CYP3A5, aldehyde dehydrogenase (ALDH3A1), and glutathione S-transferase (GSTA1) was done either through RFLP or pyrosequencing.” | 0.98 | hgnc_dict_v1 |